LifeArc and the Gates Foundation are funding seven ground-breaking new projects launched to lower the cost of monoclonal antibody production to make them more accessible globally.
Our third quarter of has been focused on cementing and building upon our influence achieved in the key government policy documents that were published just before summer, such as the industrial Strategy and Life Sciences Sector Plan. Read on for a full breakdown of what they have been doing on your behalf.
In this blog, Justin Wilson, Withers & Rogers LLP, shares his expert perspective on what the recent patent rulings from the Unified Patent Court (UPC) and the Court of Justice of the European Union (CJEU) mean in practice for biotech and pharma companies.
The fourth edition of the Tech Kickstarter Competition is now open for applications. If you are a seed or early-stage company working on a breakthrough product in life sciences, green tech, or tech/AI, this is your chance to accelerate your tech development.
This quarter has seen a cascade of government policy announcements, including the Spending Review and Industrial Strategy. Our team have been rigorously scrutinising and gearing up for the launch of the Life Sciences Sector Plan and the NHS 10-Year Health Plan, two transformative frameworks that could redefine the future of our sector.
The new site reflects Stratagem’s growth as a forward-thinking IP partner, offering clarity, simplicity and relevance across every stage of the client journey.
Our response to the Government’s consultation highlights the value of secure health data access for biotechs, the risks of uncontrolled broker use, and more.
Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
Poolbeg Pharma announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg's Republic of Korea Immunomodulator II patent application providing protection to POLB 001 for the treatment of severe influenza to December 2038.
The UKHSA Conference 2025, delivered in partnership with the FPH, will explore the full breadth of UKHSA’s work; from science-driven research to effective policy implementation.
We've responded to the joint Intellectual Property Office (IPO), Department for Science, Innovation and Technology (DSIT) and Department for Culture, Media, and Sport (DCMS) consultation on Copyright and Artificial Intelligence (AI).
Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
Pioneer Group, the life science infrastructure and venture building specialist, has joined forces with Innovate UK, The Medical Research Council (MRC) and AstraZeneca, to deliver the AI in Health Accelerator 2024/2025 Programme.
Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials.
Pioneer Group has partnered Thermo Fisher Scientific to support biotech founders on their journey towards commercialising intellectual property in the healthcare and sustainability sectors.
Therakind announces that the United States Patent and Trademark Office has granted a patent protecting the Company’s novel multi-dose, needle-free version of its dry powder nasal drug delivery system, DriDose®.
